Nature's Sunshine Products, Inc. (NATR) compared with its closest peers (ZNTL, IMRN, QTTB, VTVT, EBS): P/E 13.2 vs industry 17.2. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $271.93M | -0.7 |
| Immuron Limited (IMRN) | $271.39M | — |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| vTv Therapeutics Inc. (VTVT) | $270.06M | 119.9 |
| Emergent BioSolutions Inc. (EBS) | $262.37M | 2.3 |
| MacroGenics, Inc. (MGNX) | $257.35M | -1.4 |
| Pyxis Oncology, Inc. (PYXS) | $256.06M | -0.9 |
| Greenwich LifeSciences, Inc. (GLSI) | $244.32M | — |
| Akebia Therapeutics, Inc. (AKBA) | $243.63M | -80.3 |
| Sionna Therapeutics, Inc. (SION) | $238.27M | -21.9 |
| Stock P/E | 13.2 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -39.2% |
| vs Industry | -23.1% |
NATR overview · NATR earnings · NATR financials · NATR KPIs · NATR investor relations · NATR ownership · NATR filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.